Issues in the use of genetically engineered biologic agents for severe bronchial asthma: data from the Clinic of Northeastern Federal University
https://doi.org/10.34215/1609-1175-2025-1-76-81
Abstract
Objective. To study the course of severe bronchial asthma and the effectiveness of genetically engineered biological drugs in the Yakut population.
Materials and methods. The study included 18 Yakut patients with severe bronchial asthma being treated in the Clinic of the North-Eastern Federal University. Genetically engineered biological therapy (anti-IL-5 Mepolizumab, anti-IL-5Rα Benralizumab, anti-IL-4Rα Dupiluma, and anti-IgE Omalizumab) was carried out taking into account asthma phenotypes and comorbidities. Observation was carried out in three different periods: at initiation time, after 6, and after 12 months. Spirometric methods, laboratory tests, and ACQ-5 were used. Statistical processing was performed using the Wilcoxon test (SPSS IBM Statistics).
Results. After 12 months of genetically engineered biological therapy, improved asthma control was observed: the ACQ-5 score decreased from 2.73 ± 0.66 to 0.48 ± 0.19 (p < 0.001). The mean blood eosinophil count decreased but stayed above 150 cells/µL. External respiratory function showed positive dynamics: FVC, FEV1, modified Tiffeneau index, and PEF are improved by 23.25, 25.05, 8.93, and 26.7%, respectively.
Conclusion. Genetically engineered biological therapy has demonstrated high effectiveness in improving control of severe bronchial asthma and reducing the need for anti-inflammatory therapy.
About the Authors
A. V. Danilov
M.K. Ammosov North-Eastern Federal University"
Russian Federation
Russian Federation
Aleksey V. Danilov, Assistant Professor of the Department of Hospital therapy, Occupational Diseases and Clinical Pharmacology,
Yakutsk 677000, 27 Oyunskogo st.
V. A. Nevzorova
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
A. N. Argunova
M.K. Ammosov North-Eastern Federal University"
Russian Federation
Russian Federation
Yakutsk 677000, 27 Oyunskogo st.
Yu. A. Soloveva
M.K. Ammosov North-Eastern Federal University"
Russian Federation
Russian Federation
Yakutsk 677000, 27 Oyunskogo st.
References
1. Chuchalin AG, Avdeev SN, Aisanov ZR, Belevsky AS, Vasilyeva OS, Geppe NA, Ignatova GL, Knyazheskaya NP, Malakhov AB, Meshcheryakova NN, Nenasheva NM, Fassakhov RS, Khaitov RM, Ilyina NI, Kurbacheva OM, Astafieva NG, Demko IV, Fomina DS, Namazova-Baranova LS, Baranov AA, Vishneva EA, Novik GA. Bronchial asthma: Federal clinical guidelines for diagnosis and treatment. Pulmonologiya. 2022;32(3):393–447 (In Russ.). doi: 10.18093/0869-0189-2022-32-3-393-447
2. Bystritskaya EV, Bilichenko TN. The review of the bronchial asthma morbidity in the population of the Russian Federation. Pulmonologiya. 2022;32(5):651–60 (In Russ.). doi: 10.18093/0869-0189-2022-32-5-651-660
3. Bystritskaya EV, Bilichenko TN, Misharin Russian population due to respiratory diseases and COVID-19 in the period 2016–2021. Pulmonologiya. 2024;34(6):801–9 (In Russ.). doi: 10.18093/0869-0189-2024-34-6-801-809
4. Nazarova AA, Timofeev LF. Assessment of the relationship between morbidity among the population of the Republic of Sakha (Yakutia) and the state of the environment. Vestnik of North-Eastern Federal University. Medical Sciences. 2020;1(18):69–74 (In Russ.). doi: 10.25587/SVFU.2020.18.61533
5. Solovyova NA, Nikolaeva LE, Ogorodova LM. Polymorphism of Interleukin Genes in Bronchial Asthma in the Yakut Population. Pediatric Pharmacology. 2009;6(6):108–12 (In Russ.).
6. Shumatov VB, Prosekova EV, Dolgopolov MS, Turyanskaya AI, Kovalchuk VK, Sabynych VA. Comparative characterization of interleukin genotypes and risks of bronchial asthma phenotypes in children. Pacific Medical Journal. 2024;1:5–10 (In Russ.)]. doi: 10.34215/1609-1175-2024-1-5-10
7. Avdeev SN, Voznesensky NA, Boldina MV, Van’kova EI, Zaykova-Khelimskaya IV, Ignatova GL, Kostina NE, Kostrova IV, Kochegarova EYu, Kulbaisov AM, Leshchenko IV, Skal’skiy SV, Tikhanov DA. Overuse of short-acting β2- agonists in the Russian population with asthma: the persisting threat. Pulmonologiya. 2022; 32(5): 661–9 (In Russ.). doi: 10.18093/0869-0189-2022-32-5-661-669
8. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024. Updated May 2024. URL: www.ginasthma.org (Accessed November 5, 2024).
9. Eliseeva TI, Tush EV, Krasilnikova SV, Kuznetsova SV, Larin RA, Kubysheva NI, Khaletskaya OV, Potemina TE, Ryazantsev SV, Ignatov SK. Metabolism of the Extracellular Matrix in Bronchial Asthma (Review). Sovremennye Tehnologii v Medicine. 2018;10(4):220–7 (In Russ.). doi: 10.17691/stm2018.10.4.25
10. Kraposhina AY, Sobko EA, Demko IV, Katser AB, Kazmerchuk OV, Abramov YI. Difficult-to-treat asthma: the most significant factors impeding control. Bulletin of Physiology and Pathology of Respiration. 2024;91:23–33 (In Russ.). doi: 10.36604/1998-5029-2024-91-23-33
11. Kraposhina AY, Demko IV, Sobko EA, Katser AB, Kazmerchuk OV, Abramov YI, Kravchenko NY, Belevskij AS. Possibilities of targeted therapy for severe asthma. Moscow; 2024;64 (In Russ.).
12. Fomina DS, Ignatova GL, Kabanova TG, Kameleva AA, Kozyreva LS, Kosyakova NI, Kudelya LM, Kuzubova NA, Leshсhenko IV, Shulzhenko LV. Efficacy of benralizumab in severe eosinophilic asthma: results of a real clinical practice prospective study BEST in Russia. Pulmonologiya. 2024;34(3):441–53 (In Russ.). doi: 10.18093/0869-0189-2023-33-3-374-385
13. Kazmerchuk OV, Sobko EA, Demko IV. Achieving control of severe asthma with targeted therapy. Pulmonologiya. 2024;34(4):586–91 (In Russ.). doi: 10.18093/0869-0189-2024-34-4-586-591
14. Aisanov ZR, Kurbacheva OM, Emelyanov AV, Ignatova GL, Teichman L, Makarova JY, Fedosenko SV, Alfonso R, Elfishawy T. Burden and management of severe asthma in Russia: results from international observational study. Terapevticheskii Arkhiv. 2024;96(3):212–7 (In Russ.). doi: 10.26442/00403660.2024.03.202625
Review
For citations:
Danilov A.V., Nevzorova V.A., Argunova A.N., Soloveva Yu.A. Issues in the use of genetically engineered biologic agents for severe bronchial asthma: data from the Clinic of Northeastern Federal University. Pacific Medical Journal. 2025;(1):76-81. (In Russ.) https://doi.org/10.34215/1609-1175-2025-1-76-81
Views:
146
Email this article 